Moreover, incubation of multiple myeloma cells with doxorubicin or the alkylating agent melphalan can lead to the robust activation of NF-κB activity that confers anti-apoptotic abilities to the treated cells [41]. Here, NFKB1 is linked to plasma cell myeloma.